Novel PET imaging methods for prostate cancer

Introduction Prostate cancer is a common neoplasm but conventional imaging methods such as CT and bone scan are often insensitive. A new class of PET agents have emerged to diagnose and manage prostate cancer. Methods The relevant literature on PET imaging agents for prostate cancer was reviewed. Results This review shows a broad range of PET imaging agents, the most successful of which is prostate specific membrane antigen (PSMA) PET. Other agents either lack the sensitivity or specificity of PSMA PET. Conclusion Among the available PET agents for prostate cancer, PSMA PET has emerged as the leader. It is likely to have great impact on the diagnosis, staging and management of prostate cancer patients.

Automated summary

Among the available PET agents for prostate cancer, PSMA PET has emerged as the leader, showing greater sensitivity and specificity compared to other agents. PSMA PET is likely to have a significant impact on the diagnosis, staging, and management of prostate cancer patients.